Antimicrobial activity of ibuprofen against cystic fibrosis-associated gram-negative pathogens

Parth N. Shah, Kimberly R. Marshall-Batty, Justin A. Smolen, Jasur A. Tagaev, Qingquan Chen, Christopher A. Rodesney, Henry H. Le, Vernita D. Gordon, David E. Greenberg, Carolyn L. Cannon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Clinical trials have demonstrated the benefits of ibuprofen therapy in cystic fibrosis (CF) patients, an effect that is currently attributed to ibuprofen’s antiinflammatory properties. Yet, a few previous reports demonstrated an antimicrobial activity of ibuprofen as well, although none investigated its direct effects on the pathogens found in the CF lung, which is the focus of this work. Determination of ibuprofen’s in vitro antimicrobial activity against Pseudomonas aeruginosa and Burkholderia species strains through measurements of the endpoint number of CFU and growth kinetics showed that ibuprofen reduced the growth rate and bacterial burden of the tested strains in a dose-dependent fashion. In an in vitro Pseudomonas biofilm model, a reduction in the rate of biomass accumulation over 8 h of growth with ibuprofen treatment was observed. Next, an acute Pseudomonas pneumonia model was used to test this antimicrobial activity after the oral delivery of ibuprofen. Following intranasal inoculation, ibuprofen-treated mice exhibited lower CFU counts and improved survival compared with the control animals. Preliminary biodistribution studies performed after the delivery of ibuprofen to mice by aerosol demonstrated a rapid accumulation of ibuprofen in serum and minimum retention in lung tissue and bronchoalveolar lavage fluid. Therefore, ibuprofen-encapsulated polymeric nanoparticles (Ibu-NPs) were formulated to improve the pharmacokinetic profile. Ibu-NPs formulated for aerosol delivery inhibited the growth of P. aeruginosa in vitro and may provide a convenient dosing method. These results provide an additional explanation for the previously observed therapeutic effects of ibuprofen in CF patients and further strengthen the argument for its use by these patients.

Original languageEnglish (US)
Article numbere01574-17
JournalAntimicrobial Agents and Chemotherapy
Volume62
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Ibuprofen
Cystic Fibrosis
Bronchoalveolar Lavage Fluid
Growth
Pseudomonas
Aerosols
Nanoparticles
Pseudomonas aeruginosa
Burkholderia
Therapeutic Uses
Biofilms
Biomass
Pneumonia
Anti-Inflammatory Agents
Pharmacokinetics

Keywords

  • Antimicrobial
  • Burkholderia spp.
  • Cystic fibrosis
  • Ibuprofen
  • Nanoparticles
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Shah, P. N., Marshall-Batty, K. R., Smolen, J. A., Tagaev, J. A., Chen, Q., Rodesney, C. A., ... Cannon, C. L. (2018). Antimicrobial activity of ibuprofen against cystic fibrosis-associated gram-negative pathogens. Antimicrobial Agents and Chemotherapy, 62(3), [e01574-17]. https://doi.org/10.1128/AAC.01574-17

Antimicrobial activity of ibuprofen against cystic fibrosis-associated gram-negative pathogens. / Shah, Parth N.; Marshall-Batty, Kimberly R.; Smolen, Justin A.; Tagaev, Jasur A.; Chen, Qingquan; Rodesney, Christopher A.; Le, Henry H.; Gordon, Vernita D.; Greenberg, David E.; Cannon, Carolyn L.

In: Antimicrobial Agents and Chemotherapy, Vol. 62, No. 3, e01574-17, 01.03.2018.

Research output: Contribution to journalArticle

Shah, PN, Marshall-Batty, KR, Smolen, JA, Tagaev, JA, Chen, Q, Rodesney, CA, Le, HH, Gordon, VD, Greenberg, DE & Cannon, CL 2018, 'Antimicrobial activity of ibuprofen against cystic fibrosis-associated gram-negative pathogens', Antimicrobial Agents and Chemotherapy, vol. 62, no. 3, e01574-17. https://doi.org/10.1128/AAC.01574-17
Shah, Parth N. ; Marshall-Batty, Kimberly R. ; Smolen, Justin A. ; Tagaev, Jasur A. ; Chen, Qingquan ; Rodesney, Christopher A. ; Le, Henry H. ; Gordon, Vernita D. ; Greenberg, David E. ; Cannon, Carolyn L. / Antimicrobial activity of ibuprofen against cystic fibrosis-associated gram-negative pathogens. In: Antimicrobial Agents and Chemotherapy. 2018 ; Vol. 62, No. 3.
@article{dd00c4a9c1854f7597ea721f46a40c8b,
title = "Antimicrobial activity of ibuprofen against cystic fibrosis-associated gram-negative pathogens",
abstract = "Clinical trials have demonstrated the benefits of ibuprofen therapy in cystic fibrosis (CF) patients, an effect that is currently attributed to ibuprofen’s antiinflammatory properties. Yet, a few previous reports demonstrated an antimicrobial activity of ibuprofen as well, although none investigated its direct effects on the pathogens found in the CF lung, which is the focus of this work. Determination of ibuprofen’s in vitro antimicrobial activity against Pseudomonas aeruginosa and Burkholderia species strains through measurements of the endpoint number of CFU and growth kinetics showed that ibuprofen reduced the growth rate and bacterial burden of the tested strains in a dose-dependent fashion. In an in vitro Pseudomonas biofilm model, a reduction in the rate of biomass accumulation over 8 h of growth with ibuprofen treatment was observed. Next, an acute Pseudomonas pneumonia model was used to test this antimicrobial activity after the oral delivery of ibuprofen. Following intranasal inoculation, ibuprofen-treated mice exhibited lower CFU counts and improved survival compared with the control animals. Preliminary biodistribution studies performed after the delivery of ibuprofen to mice by aerosol demonstrated a rapid accumulation of ibuprofen in serum and minimum retention in lung tissue and bronchoalveolar lavage fluid. Therefore, ibuprofen-encapsulated polymeric nanoparticles (Ibu-NPs) were formulated to improve the pharmacokinetic profile. Ibu-NPs formulated for aerosol delivery inhibited the growth of P. aeruginosa in vitro and may provide a convenient dosing method. These results provide an additional explanation for the previously observed therapeutic effects of ibuprofen in CF patients and further strengthen the argument for its use by these patients.",
keywords = "Antimicrobial, Burkholderia spp., Cystic fibrosis, Ibuprofen, Nanoparticles, Pseudomonas aeruginosa",
author = "Shah, {Parth N.} and Marshall-Batty, {Kimberly R.} and Smolen, {Justin A.} and Tagaev, {Jasur A.} and Qingquan Chen and Rodesney, {Christopher A.} and Le, {Henry H.} and Gordon, {Vernita D.} and Greenberg, {David E.} and Cannon, {Carolyn L.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1128/AAC.01574-17",
language = "English (US)",
volume = "62",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Antimicrobial activity of ibuprofen against cystic fibrosis-associated gram-negative pathogens

AU - Shah, Parth N.

AU - Marshall-Batty, Kimberly R.

AU - Smolen, Justin A.

AU - Tagaev, Jasur A.

AU - Chen, Qingquan

AU - Rodesney, Christopher A.

AU - Le, Henry H.

AU - Gordon, Vernita D.

AU - Greenberg, David E.

AU - Cannon, Carolyn L.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Clinical trials have demonstrated the benefits of ibuprofen therapy in cystic fibrosis (CF) patients, an effect that is currently attributed to ibuprofen’s antiinflammatory properties. Yet, a few previous reports demonstrated an antimicrobial activity of ibuprofen as well, although none investigated its direct effects on the pathogens found in the CF lung, which is the focus of this work. Determination of ibuprofen’s in vitro antimicrobial activity against Pseudomonas aeruginosa and Burkholderia species strains through measurements of the endpoint number of CFU and growth kinetics showed that ibuprofen reduced the growth rate and bacterial burden of the tested strains in a dose-dependent fashion. In an in vitro Pseudomonas biofilm model, a reduction in the rate of biomass accumulation over 8 h of growth with ibuprofen treatment was observed. Next, an acute Pseudomonas pneumonia model was used to test this antimicrobial activity after the oral delivery of ibuprofen. Following intranasal inoculation, ibuprofen-treated mice exhibited lower CFU counts and improved survival compared with the control animals. Preliminary biodistribution studies performed after the delivery of ibuprofen to mice by aerosol demonstrated a rapid accumulation of ibuprofen in serum and minimum retention in lung tissue and bronchoalveolar lavage fluid. Therefore, ibuprofen-encapsulated polymeric nanoparticles (Ibu-NPs) were formulated to improve the pharmacokinetic profile. Ibu-NPs formulated for aerosol delivery inhibited the growth of P. aeruginosa in vitro and may provide a convenient dosing method. These results provide an additional explanation for the previously observed therapeutic effects of ibuprofen in CF patients and further strengthen the argument for its use by these patients.

AB - Clinical trials have demonstrated the benefits of ibuprofen therapy in cystic fibrosis (CF) patients, an effect that is currently attributed to ibuprofen’s antiinflammatory properties. Yet, a few previous reports demonstrated an antimicrobial activity of ibuprofen as well, although none investigated its direct effects on the pathogens found in the CF lung, which is the focus of this work. Determination of ibuprofen’s in vitro antimicrobial activity against Pseudomonas aeruginosa and Burkholderia species strains through measurements of the endpoint number of CFU and growth kinetics showed that ibuprofen reduced the growth rate and bacterial burden of the tested strains in a dose-dependent fashion. In an in vitro Pseudomonas biofilm model, a reduction in the rate of biomass accumulation over 8 h of growth with ibuprofen treatment was observed. Next, an acute Pseudomonas pneumonia model was used to test this antimicrobial activity after the oral delivery of ibuprofen. Following intranasal inoculation, ibuprofen-treated mice exhibited lower CFU counts and improved survival compared with the control animals. Preliminary biodistribution studies performed after the delivery of ibuprofen to mice by aerosol demonstrated a rapid accumulation of ibuprofen in serum and minimum retention in lung tissue and bronchoalveolar lavage fluid. Therefore, ibuprofen-encapsulated polymeric nanoparticles (Ibu-NPs) were formulated to improve the pharmacokinetic profile. Ibu-NPs formulated for aerosol delivery inhibited the growth of P. aeruginosa in vitro and may provide a convenient dosing method. These results provide an additional explanation for the previously observed therapeutic effects of ibuprofen in CF patients and further strengthen the argument for its use by these patients.

KW - Antimicrobial

KW - Burkholderia spp.

KW - Cystic fibrosis

KW - Ibuprofen

KW - Nanoparticles

KW - Pseudomonas aeruginosa

UR - http://www.scopus.com/inward/record.url?scp=85042435838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042435838&partnerID=8YFLogxK

U2 - 10.1128/AAC.01574-17

DO - 10.1128/AAC.01574-17

M3 - Article

C2 - 29311081

AN - SCOPUS:85042435838

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

M1 - e01574-17

ER -